Stockhouse.com: Taking it to the street
Latest Broadcasts
V.ARD
Technology-Internet
T.FR
Natural Resources
V.AIX
Natural Resources.
OMCY
Internet/Technology
V.KTN
Natural Resources, Metals and Mining
T.ND
Natural Resources
An excellent place to start your search for new investments!
add to favorites print

Drug news a bad trip for investors.

Acadia Pharmaceuticals (NASDAQ: ACAD, Stock Forum) shares lost about half of its market value when news hit the market that the company's experimental schizophrenia drug proved no better than existing drugs. The shares crashed as low as $4.30 against a 52-week high of $17.33.

Investors had a massive bet on the drug, and no wonder. In the last quarter, the company lost $17.6 million on $800,000 in revenue. ACAD still has a Parkinson's disease treatment, but that is in Phase III trials and there is no guarantee that it will make it to market.

In many ways, ACAD is typical of the risks that face biotech investors. The company's success has a foundation in two or three products, none of which may make it to market. Those that do get FCC approval may also face an unknown competitive environment.

Acadia has $106 million on its balance sheet, but burned through about $20 million last quarter. That means the firm will be facing real problems a year from now, if it does not come up with something spectacular.

 

ABOUT THE AUTHOR
From the news desk of 24/7 Wall St.

This report was prepared by 24/7 Wall St., LLC exclusively for Stockhouse. 

 
print
 
Stockhouse Conflict and Disclosure Policy:

Stockgroup Media Inc., owners and operators of Stockhouse.com, has established the following rules to ensure that there is no appearance of impropriety on the part of any Stockhouse Editorial writers ("Writers"). The content of Stockhouse Editorial articles (the "Articles") are the opinion of the Writer and any reliance on the content of these articles is at your sole risk. Our Writers are not registered investment advisors. You should not make any kind of investment decision in relation to Articles or stocks discussed in them without obtaining advice from a registered investment advisor.

Facts relied upon by our Writers are generally provided by the subject companies or gathered by our Writers from other public and/or private sources. These facts may be in error and if so, the opinions of our Writers may be materially different.

Writers may own, buy, or sell shares in public companies mentioned in their Articles, but in the Article they must prominently state their ownership position. Thus, a conflict may exist. Writers are not permitted to write Articles that attempt to benefit persons connected to the Writer, such as family or friends, except where disclosure is made in the same way as if the Writer him/herself owns stock.

Writers cannot solicit, accept, or agree to receive anything of value given or paid with the intent of influencing their Articles.

Stockhouse notifies each Writer about these rules, and we rely on the integrity of our Writers to ensure that our rules are followed.

 
 
 
 
 
Today's Feature  
 
First Majestic Silver Corp
First Majestic Silver Corp. is a pure silver producing mining company focused in Mexico. The Company strives for continued growth with a proven aggressive growth strategy based on acquisition and development of advance staged silver projects. First Majestic has excelled in acquisition of long term sustainable projects and has set itself apart from others in the silver space lead by President and CEO, Keith Neumeyer, founder of First Quantum Minerals, a successful copper company; alongside ...